PK parameters of CNP immunoreactivity after a single intravenous administration of C-Type Natriuretic Peptide (CNP) (1-22), human:
Dose (nM/kg) |
AUC0-∞ (pM·min/mL) |
MRT0-∞ (min) |
T1/2 (min) |
CLtot (mL/min/kg) |
Vdss (mL/kg) |
20 |
320±54 |
1.02±0.18 |
1.42±0.45 |
63.9±11.9 |
64.2±5.1 |
PK parameters of CNP immunoreactivity after a single subcutaneous administration of C-Type Natriuretic Peptide (CNP) (1-22), human:
Dose (nM/kg) |
Cmax (pM/mL) |
Tmax (min) |
AUC0-∞ (pM·min/mL) |
MRT0-∞ (min) |
T1/2 (min) |
BA (%) |
50 |
9.02±3.74 |
5.0±0.0 |
152±73 |
13.9±3.4 |
10.0±5.0 |
19±9 |
Each value represents the mean±SD of 3 rats. MRT=mean residence time, CL
tot=total clearance, T
1/2=half-life period, BA=bioavailability.
i.c.v. administration of C-Type Natriuretic Peptide (CNP) (1-22) in a dose of 2 nM induces an increase in the severity of picrotoxin-kindled convulsions 24 and 48 hrs after application of the peptide.
Medlife has not independently confirmed the accuracy of these methods. They are for reference only.